The efficacy and toxicity of belotecan (CKD-602), a camptothecin analogue topoisomerase I inhibitor, in patients with recurrent or refractory epithelial ovarian cancer

Journal of Chemotherapy

Volumn 22, Issue 3, 2010, Pages 197-200

  Kim, Yong Man ^a   Lee, Shin Wha ^a   Kim, Dae Yeon ^a   Kim, Jong Hyeok ^a   Nam, Joo Hyun ^a   Kim, Young Tak ^a  

^a University of Ulsan   (South Korea)

Author keywords

Belotecan; Camptothecin; Epithelial ovarian cancer; Recurrent ovarian cancer

Indexed keywords

BELOTECAN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; AGED; ANEMIA; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RECURRENT CANCER; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 78650244456     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2010.22.3.197     Document Type: Article

References (40)

1. Boring CC, Squires TS, Tong T. Cancer Statistics, 1991. CA Cancer J Clin 1991; 41: 19-36.
2. Lee JH, Lee JM, Kim JK, Ahn SK, Lee SJ, Kim MY, et al. Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor. Arch Pharm Res 1998; 21(5): 581-590.
3. Crul M. CKD-602. Chong Kun Dang. Curr Opin Investig Drugs 2003; 4: 1455-1459.
4. Lee JH, Lee JM, Lim KH, Kim JK, Ahn SK, Bang YJ, et al. Preclinical and phase I clinical studies with Ckd 602, a novel camptothecin derivative. Ann N Y Acad Sci 2000; 922: 324-325. (Pubitemid 32050270)
5. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92(3): 205-216.
6. Salzberg M, Thurlimann B, Bonnefois H, Fink D, Rochlitz C, von Moos R, et al. Current concepts of treatment strategies in advanced or recurrent ovarian cancer. Oncology 2005; 68(4-6): 293-298. (Pubitemid 41160956)
7. Creemers GJ, Bolis G, Gore M, Scarfone G, Lacave AJ. Guastalla JP, et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 1996; 14(12): 3056-3061. (Pubitemid 26408798)
8. Kudelka AP, Tresukosol D, Edwards CL, Freedman RS, Levenback C, Chantarawiroj P, et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 1996; 14(5): 1552-1557. (Pubitemid 26134213)
9. Swisher EM, Mutch DG, Rader JS, Elbendary A, Herzog TJ. Topotecan in platinum- and paclitaxel-resistant ovarian cancer. Gynecol Oncol 1997; 66(3): 480-486. (Pubitemid 27388142)
10. Bookman MA, Malmstrom H, Bolis G, Gordon A, Lissoni A, Krebs JB, et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 1998; 16(10): 3345-3352. (Pubitemid 28481631)
11. McGuire WP, Blessing JA, Bookman MA, Lentz SS, Dunton CJ. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2000; 18(5): 1062-1067. (Pubitemid 30123784)
12. Takeuchi S, Takamizawa H, Takeda Y, Ohkawa T, Tamaya T. Noda K, et al. An early phase II study of CPT-11 in gynecologic cancers: Research Group of CPT-11 in Gynecologic Cancers. Gan To Kagaku Ryoho 1991; 18(4): 579-584.
13. Takeuchi S, Dobashi K, Fujimoto S, Tanaka K, Suzuki M, Terashima Y, et al. A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer: Research Groups of CPT-11 in Gynecologic Cancers. Gan To Kagaku Ryoho 1991; 18(10): 1681-1689.
14. Sugiyama T, Nishida T, Kataoka A, Imaishi K, Komai K, Ushijima K, et al. Combination of irinotecan hydrochloride (CPT-11) and cisplatin as a new regimen for patients with advanced ovarian cancer. Nippon Sanka Fujinka Gakkai Zasshi 1996; 48(9): 827-834. (Pubitemid 26325769)
15. Bodurka DC, Levenback C, Wolf JK, Gano J, Wharton JT, Kavanagh JJ, et al. Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer. J Clin Oncol 2003; 21(2): 291-297. (Pubitemid 46606158)
16. Gordon AN, Granai CO, Rose PG, Hainsworth J, Lopez A, Weissman C, et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 2000; 18(17): 3093-3100.
17. Safra T, Groshen S, Jeffers S, Tsao-Wei DD, Zhou L, Muderspach L, et al. Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin: analysis of toxicities and predictors of outcome. Cancer 2001; 91(1): 90-100. (Pubitemid 32052618)
18. Johnston SR, Gore ME, Caelyx: Phase II studies in ovarian cancer. Eur J Cancer 2001; 37(Suppl 9): S8-S14. (Pubitemid 33734673)
19. Arcuri C, Sorio R, Tognon G, Gambino A, Scalone S, Lucenti A, et al. A phase II study of liposomal doxorubicin in recurrent epithelial ovarian carcinoma. Tumori 2004; 90(6): 556-561.
20. Lund B, Hansen OP, Theilade K, Hansen M, Neijt JP. Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 1994; 86(20): 1530-1533. (Pubitemid 24330217)
21. Shapiro JD, Millward MJ, Rischin D, Michael M, Walcher V, Francis PA, et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol 1996; 63(1): 89-93. (Pubitemid 26337972)
22. von Minckwitz G, Bauknecht T, Visseren-Grul CM, Neijt JP. Phase II study of gemcitabine in ovarian cancer. Ann Oncol 1999; 10(7): 853-855. (Pubitemid 29368004)
23. D'Agostino G, Amant F, Berteloot P, Scambia G, Vergote I. Phase II study of gemcitabine in recurrent platinum- and paclitaxel-resistant ovarian cancer. Gynecol Oncol 2003; 88(3): 266-269. (Pubitemid 36331977)
24. George MJ, Heron JF, Kerbrat P, Chauvergne J, Goupil A, Lebrun D, et al. Navelbine in advanced ovarian epithelial cancer: a study of the French oncology centers. Semin Oncol 1989; 16(Suppl 2): 30-32. (Pubitemid 19137825)
25. Burger RA, DiSaia PJ, Roberts JA, O'rourke M, Gershenson DM, Homesley HD, et al. Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer. Gynecol Oncol 1999; 72(2): 148-153.
26. Bajetta E, Di Leo A, Biganzoli L, Mariani L, Cappuzzo F. Di Bartolomeo M, et al. Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease. J Clin Oncol 1990; 14(9): 2546-2551.
27. Sorensen P, Hoyer M, Jakobsen A, Malmstrom H, Havsteen H, Bertelsen K. Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma. Gynecol Oncol 2001; 81(1): 58-62.
28. Gershenson DM, Burke TW, Morris M, Bast RC, Guaspari A, Hohneker J, et al. A phase I study of a daily x3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer. Gynecol Oncol 1998; 70(3): 404-409. (Pubitemid 28473642)
29. ten Bokkel Huinink W, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997; 15(6): 2183-2193.
30. Trimble EL, Adams JD, Vena D, Hawkins MJ, Friedman MA, Fisherman JS, et al. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol 1993; 11(12): 2405-2410. (Pubitemid 23353971)
31. du Bois A, Lück HJ, Buser K, Meerpohl HG, Sessa C, Klaassen U, et al. Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with platinum. Eur J Cancer 1997; 33(3): 379-384.
32. Ozols RE, Ostchega Y, Curt G, Young RC. High-dose carboplatin in refractory ovarian cancer patients. J Clin Oncol 1987; 5(2): 197-201. (Pubitemid 17021599)
33. Kavanagh J, Tresukosol D, Edwards C, Freedman R, Gonzalez de Leon C, Fishman A, et al. Carboplatin reinduction after taxane in patients with platinum- refractory epithelial ovarian cancer. J Clin Oncol 1995; 13(7): 1584-1588.
34. Francis P, Schneider J, Hann L, Balmaceda C, Barakat R, Phillips M, et al. Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol 1994; 12(11): 2301-2308. (Pubitemid 24346699)
35. Katsumata N, Tsunematsu R, Tanaka K, Terashima Y, Ogita S, Hoshiai H, et al. A phase II trial of docetaxel in platinum pre-treated patients with advanced epithelial ovarian cancer: A Japanese Cooperative Study. Ann Oncol 2000; 11(12): 1531-1536. (Pubitemid 32104750)
36. Rose PG, Blessing JA, Ball HG, Hoffman J, Warshal D, DeGeest K, et al. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group sludy. Gynecol Oncol 2003; 88(2): 130-135. (Pubitemid 36263370)
37. Boehmer Ch, Jaeger W. Capecitabine in treatment of platinum-resistant recurrent ovarian cancer. Anticancer Res 2002; 22(1A): 439-443. (Pubitemid 34475336)
38. Vasey PA, McMahon L, Paul J, Reed N, Kaye SB. A phase II trial of capecitabine (Xeloda) in recurrent ovarian cancer. Br J Cancer 2003; 89(10): 1843-1848. (Pubitemid 37533257)
39. Rischin D, Phillips KA, Friedlander M, Harnett P, Quinn M, Richardson G, et al. A phase II trial of capecitabine in heavily pre-treated platinum-resistant ovarian cancer. Gynecol Oncol 2004; 93(2): 417-421.
40. Lee HP, Seo SS, Ryu SY, Kim JH, Bang YJ, Park SY, et al. Phase H evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer. Gynecol Oncol 2008; 109(3): 359-363.